ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use

Chen, Feili; Pang, Diwen; Guo, Hanguo; Ou, Qiuxiang; Wu, Xue; Jiang, Xinmiao; Wei, Xiaojuan; Liu, Sichu; Huang, Ling; Liang, Zhanli; Zhou, Dong*; Li, Wenyu*广东省人民医院
Cancer Medicine2020-11DOI: 10.1002/cam4.3499
21被引13阅读
引用收藏
分享

摘要

Ibrutinib-based combination therapy with high-dose methotrexate (HD-MTX) has recently shown clinical activity against relapse/refractory (R/R) primary central nervous system lymphoma (PCNSL). Herein, we report our real-world experience of treating 11 newly diagnosed PCNSL patients with the ibrutinib/MTX combination. HD-MTX was given at 3.5 g/m(2)every 2-week for eight doses. Ibrutinib was held upon HD-MTX infusion until clearance and was administered daily post-induction until disease progression, intolerable toxicity, or death. Nine out of 11 patients completed the induction phase and received ibrutinib as maintenance therapy. An objective response rate (ORR) of 82% (9/11) was observed including complete response (64%) and partial response (18%). The median progression-free survival (PFS) was 7.4 months while the median overall survival (OS) was not reached. The ibrutinib/MTX combination was well tolerated in these treatment-naive PCNSL patients with an acceptable safety profile. Moreover, the longitudinal analysis of cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) revealed that CSF ctDNA detection was closely associated with tumor response, and sustained tumor responses correlated with the clearance of ctDNA from the CSF. In sum, our data not only demonstrated the clinical benefit of the ibrutinib and HD-MTX combination regimen in treating newly diagnosed PCNSL patients in a real-world setting, but also highlighted the significance of liquid biopsy including CSF ctDNA in tracing tumor burden and assessing treatment response.

学科与关键词

关键词
CENTRAL-NERVOUS-SYSTEMTYROSINE KINASEPHASE-IILENALIDOMIDE
相关
加载中…
  • High-Dose Methotrexate, Ibrutinib and Temozolomide (MIT) for the Treatment of Newly Diagnosed Primary Central Nervous System Lymphoma: A Multi-Center Prospective Phase II Study
    Ping, Liqin; Wang, Xiaoxiao; Gao, Yan; Bai, Bing; Huang, He; Cai, Linbo; Zhou, Hui; Shan, Changguo; Li, Zhiming; Lai, Mingyao; He, Haixia; Huang, Cheng; Chen, Haoqing; Feng, Ru; Huang, Huiqiang65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
  • Efficacy and Safety of Orelabrutinib-Containing Regime (TORM) As First-Line Therapy in Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis
    Wu, Shaojie; Tu, Sanfang; Zhou, Zhenjun; Sun, Xinlin; Wu, Anqin; Wang, Lei; Li, Yuhua65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
  • Long-term Complete Remission of Decitabine-Primed Tandem CD19/CD22 CAR-T Therapy with PD-1 and BTK Inhibitors Maintenance in a Refractory Primary Central Nervous System Lymphoma Patient
    Zou, Rui; Zhou, Xiao; Liu, Hailing; Wang, Peng; Xia, Fan; Kang, Liqing; Yu, Lei; Wu, Depei*; Jin, Zhengming*; Qu, Changju*Cancer Research and Treatment, 2023, 55(4): 1363-1368.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancer Medicine
发表日期
2020-11
卷期
第 9 卷, 第 22 期
页码
8676-8684
DOI
10.1002/cam4.3499
语言
ENGLISH
期刊收录
NSL.SCIE
期刊等级
3区
成果收录
SCIE
资助标注
Science and Technology Planning Project Foundation of Guangdong Province, China [2016A050502028]

作者

  • C

    Chen, Feili (第一作者)

    guangdong prov peoples hosp

  • P

    Pang, Diwen

    guangdong prov peoples hosp

查看全部 12 位作者收起作者
  • G

    Guo, Hanguo

    guangdong prov peoples hosp

  • O

    Ou, Qiuxiang

  • W

    Wu, Xue

    guangdong prov peoples hosp

  • J

    Jiang, Xinmiao

    guangdong prov peoples hosp

  • W

    Wei, Xiaojuan

    guangdong prov peoples hosp

  • L

    Liu, Sichu

    guangdong prov peoples hosp

  • H

    Huang, Ling

    guangdong prov peoples hosp

  • L

    Liang, Zhanli

    guangdong prov peoples hosp

  • Z

    Zhou, Dong (通讯)

    guangdong prov peoples hosp

  • L

    Li, Wenyu (通讯)

    guangdong prov peoples hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417